Compare Geo Group Inc (The) REIT (GEO) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Geo Group Inc (The) REIT vs Natera Inc. Common Stock — how do they compare? Geo Group Inc (The) REIT trades at $30.87 (market cap $4.24B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 13.5× Geo Group Inc (The) REIT's market cap, and Geo Group Inc (The) REIT is more actively traded (1,580,830 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Geo Group Inc (The) REIT for 6 Days and Natera Inc. Common Stock for 0 Days on average.
| GEO | NTRA | |
|---|---|---|
Market Cap | $4.24B | $57.03B |
Volume | 1,580,830 | 1,131,157 |
Sector | Industrials | Health |
52-Week High | $32.77 | $425.64 |
52-Week Low | $13.26 | $179.42 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $5.79B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GEO trades at $32.19, up 1.45% today, with a bullish technical signal from moving averages. Recent earnings beats in Q1 and Q2 2026, alongside a net income margin of 10.31% and ROE of 20.11%, highlight strong profitability. The company recently sold its Adelanto facilities for $950 million and increased its share repurchase authorization to $1.25 billion, signaling financial strength and shareholder returns.
The outlook is positive, supported by analyst consensus (66.7% buy ratings) and recent Zacks upgrades to Strong Buy. Key opportunities include earnings momentum and strategic asset sales, while risks involve debt management and potential regulatory scrutiny. The stock's valuation, with a P/E of 15.18, appears reasonable given growth prospects.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Geo Group Inc (The) REIT
The GEO Group provides correctional, detention, and community reentry services. Its operations include secure facilities, electronic monitoring, and support programs for individuals in the criminal-justice system.
Read more on GEO →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
